Literature DB >> 4034927

Evaluation of radio- and chemotoxic effects of 125I-UdR on tumour growth and host survival.

R Porschen, W Porschen, H Mühlensiepen, L E Feinendegen.   

Abstract

The toxicity of 5-iodo-2'-deoxyuridine (I-UdR) was assayed in male C57 BL/6J mice bearing the syngeneic mammary adenocarcinoma EO 771 by injecting different doses of 'cold' I-UdR or 125-iodine labelled I-UdR. Host survival, tumour growth, DNA-precursor incorporation, whole-body retention and tumour activity loss rates were chosen as biological end points. There was no measurable effect on host survival up to doses of 5 micrograms I-UdR or 50 microCi 125I-UdR per mouse during a mean life-span of 25 days. Adjusted to a constant amount of 0.55 micrograms I-UdR/mouse, radiotoxicity of 125I-UdR on tumour growth (up to 17 days after implantation), tracer incorporation, whole-body and tumour retention (up to 12 days after 125I-UdR injection) could be excluded up to a dosage of 50 microCi 125I-UdR/mouse. It is concluded that in situ evaluation of tumour activity loss rates in carcinoma EO 771 is not disturbed by toxic effects of I-UdR or 125I-UdR within the dose limits mentioned.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4034927     DOI: 10.1007/bf01209525

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  20 in total

1.  DEOXYRIBONUCLEIC ACID METABOLISM IN VIVO: I. CELL PROLIFERATION AND DEATH AS MEASURED BY INCORPORATION AND ELIMINATION OF IODODEOXYURIDINE.

Authors:  W L HUGHES; S L COMMERFORD; D GITLIN; R C KRUEGER; B SCHULTZE; V SHAH; P REILLY
Journal:  Fed Proc       Date:  1964 May-Jun

2.  RNA TURNOVER IN NORMAL RAT BONE MARROW.

Authors:  L E FEINENDEGEN; V P BOND; E P CRONKITE; W L HUGHES
Journal:  Ann N Y Acad Sci       Date:  1964-02-28       Impact factor: 5.691

3.  Natural and asparaginase induced death of L5178Y leukemia cells in vivo.

Authors:  K G Hofer; J DiBenedetto; W L Hughes
Journal:  Z Krebsforsch       Date:  1970-11-20

4.  3H-5-iodo-2'-deoxyuridine toxicity. Problems in cell proliferation studies.

Authors:  L A Dethlefsen
Journal:  Cell Tissue Kinet       Date:  1974-05

5.  [In vivo determination of the cell loss rate in experimental neoplasms using radioactively marked idoxuridine].

Authors:  W Porschen; L Feinendegen
Journal:  Strahlentherapie       Date:  1969-06

6.  Biological stability of 5-iodo-2'-deoxyuridine labelled with iodine-125 after its incorporation into the deoxyribonucleic acid of the mouse.

Authors:  S L Commerford
Journal:  Nature       Date:  1965-05-29       Impact factor: 49.962

7.  Radiotoxicity of intranuclear tritium, 125 iodine and 131 iodine.

Authors:  K G Hofer; W L Hughes
Journal:  Radiat Res       Date:  1971-07       Impact factor: 2.841

8.  Studies in a tumor spectrum. I. Comparison of the action of methylbis (2-chloroethyl)amine and 3-bis(2-chloroethyl)aminomethyl-4-methoxymethyl -5-hydroxy-6-methylpyridine on the growth of a variety of mouse and rat tumors.

Authors:  K SUGIURA; C C STOCK
Journal:  Cancer       Date:  1952-03       Impact factor: 6.860

9.  Cell loss from three established lines of the C3H mouse mammary tumor: a comparison of the 125I-UdR and the 3H-TdR-autoradiographic methods.

Authors:  L A Dethlefsen; J Sorenson; J Snively
Journal:  Cell Tissue Kinet       Date:  1977-09

10.  Reutilization of 131I-5-iodo-2'-deoxyuridine as compared to 3H-thymidine in mouse duodenum and mammary tumor.

Authors:  L A Dethlefsen
Journal:  J Natl Cancer Inst       Date:  1970-04       Impact factor: 13.506

View more
  2 in total

1.  Analytical techniques for boron and boron 10 analysis in a solid experimental tumor EO. 771.

Authors:  W Porschen; J Marx; F Dallacker; H Mückter; T Böhmel; R Fairchild; L E Feinendegen
Journal:  Radiat Environ Biophys       Date:  1987       Impact factor: 1.925

Review 2.  EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty.

Authors:  Augustin Le Naour; Adrien Rossary; Marie-Paule Vasson
Journal:  Cancer Med       Date:  2020-10-07       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.